The research in our team is focused on the development of novel treatment strategies to target prostate cancers and pancreatic cancers using genetically modified viruses that target, replicate and kill cancer cells (replication-selective oncolytic viruses) but leave normal cells unharmed.
The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6-integrins efficiently eliminates pancreatic cancer cells. Molecular Cancer Therapeutics (2018) 17 575-587. PMID: 29367266
Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy. Oncogenesis (2018) 7(1):6. PMID: 29362360
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11. Oncotarget (2016) 7(13):15703-24. PMID: 26872382
Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant (AdΔΔ) in prostate and pancreatic cancers. Clin Cancer Res (2010) 16(2):541-53. PMID: 20068104
The recent market approval of the first oncolytic immunotherapy, the herpes virus (T-Vec), has demonstrated the feasibility and effectiveness of these biotherapeutics. The focus in our team is on developing potent oncolytic, anti-cancer immune boosting adenoviral mutants that act in synergy with current clinical therapeutics. The specific aims of the research are:
The overall goal of the team is to develop improved therapies for late stage, currently treatment-resistant cancers, by constructing potent tumour specific oncolytic viruses to be investigated and evaluated in combination with therapeutics acting through different mechanisms.
Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer Stella Man YK, Foster J, Carapuça E et al. Scientific Reports (2019) 9(7)
Advances in oncolytic adenovirus therapy for pancreatic cancer. Nattress CB, Halldén G Cancer Lett (2018) 434(2) 56-69
Designer Oncolytic Adenovirus: Coming of Age. Baker AT, Aguirre-Hernández C, Halldén G et al. Cancers (Basel) (2018) 10(2)
The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells Man YKS, Davies JA, Coughlan L et al. Molecular Cancer Therapeutics (2018) 17(7) 575-587
Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus AdΔΔ through Bcl-2-dependent attenuation of autophagy Aguirre-Hernández C, Maya-Pineda H, Millán JS et al. Oncogenesis (2018) 7(7)
Targeting pancreatic and prostate cancer with E1B19K-deleted oncolytic adenoviruses Hallden G HUMAN GENE THERAPY (2017) 28(1) A6-A6
The adenoviral Ad Delta Delta mutant enhances mitoxantrone-induced apoptosis and attenuates drug-induced autophagy in prostate cancer cells. Aguirre-Hernandez C, Millan JS, Hallden G (2016) (11)
The adenoviral AdDD mutant enhances mitoxantrone-induced cell death by promoting apoptosis and attenuating autophagy in prostate cancer cells. Hernandez CA, Hallden G HUMAN GENE THERAPY (2016) 27(11) A5-A6
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11. Pantelidou C, Cherubini G, Lemoine NR et al. Oncotarget (2016) 7(2) 15703-15724
Oncolytic adenoviral mutants deleted in the anti-apoptotic E1B19K gene sensitize pancreatic cancer cells to drug-induced DNA damage Pantelidou C, Man YKS, Coughlan L et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016) 38(11) S58-S58
Dr Lauren Maskell
Medical BSc student
Mr Callum B. Nattress
Visiting postgraduate MSc student
Ms Ines Garcia Rodriguez
I joined the Barts Cancer Institute, in November 2004, as a Lecturer starting a Cancer Gene Therapy team, funded by the Flavell Bequest Programme in Prostate Cancer Gene Therapy. I completed my BSc at the University of Stockholm and Karolinska Institute, and my PhD at UC Berkeley in the USA. My postdoctoral training was in endocrinology, and cell and molecular biology at UC Berkeley, in oncolytic viruses at Onyx Pharmaceuticals (Richmond, CA, USA) and the Molecular Oncology Unit at Hammersmith Hospital in London.
In 2008 I was awarded my PGCAP (Postgraduate Certificate in Academic Practice) in teaching and learning from QMUL. In 2014 I was promoted to Reader in Cancer Gene Therapy and have focused my work on developing improved treatments for currently incurable prostate and pancreatic cancers.